BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Millonig G, Graziadei IW, Freund MC, Jaschke W, Stadlmann S, Ladurner R, Margreiter R, Vogel W. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2007;13:272-279. [PMID: 17256758 DOI: 10.1002/lt.21033] [Cited by in Crossref: 183] [Cited by in F6Publishing: 143] [Article Influence: 13.1] [Reference Citation Analysis]
Number Citing Articles
1 Guy J, Kelley RK, Roberts J, Kerlan R, Yao F, Terrault N. Multidisciplinary management of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2012;10:354-362. [PMID: 22083023 DOI: 10.1016/j.cgh.2011.11.008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
2 Nicolini D, Svegliati-Baroni G, Candelari R, Mincarelli C, Mandolesi A, Bearzi I, Mocchegiani F, Vecchi A, Montalti R, Benedetti A, Risaliti A, Vivarelli M. Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation. World J Gastroenterol 2013;19:5622-32. [PMID: 24039354 DOI: 10.3748/wjg.v19.i34.5622] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
3 Mehta N, Yao FY. Moving past “One size (and number) fits all” in the selection of candidates with hepatocellular carcinoma for liver transplantation. Liver Transpl. 2013;19:1055-1058. [PMID: 23959652 DOI: 10.1002/lt.23730] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
4 Oligane HC, Close ON, Xing M, Kim HS. Bridging locoregional therapy: Longitudinal trends and outcomes in patients with hepatocellular carcinoma. Transplant Rev (Orlando) 2017;31:136-43. [PMID: 28214240 DOI: 10.1016/j.trre.2017.01.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
5 Kumaran V. Role of liver transplantation for hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:S97-S103. [PMID: 25755618 DOI: 10.1016/j.jceh.2014.01.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
6 Silva MF, Sherman M. Criteria for liver transplantation for HCC: what should the limits be? J Hepatol 2011;55:1137-47. [PMID: 21718672 DOI: 10.1016/j.jhep.2011.05.012] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
7 Sapisochin G, Barry A, Doherty M, Fischer S, Goldaracena N, Rosales R, Russo M, Beecroft R, Ghanekar A, Bhat M, Brierley J, Greig PD, Knox JJ, Dawson LA, Grant DR. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol. 2017;67:92-99. [PMID: 28257902 DOI: 10.1016/j.jhep.2017.02.022] [Cited by in Crossref: 113] [Cited by in F6Publishing: 73] [Article Influence: 28.3] [Reference Citation Analysis]
8 Fahrner R, Dondorf F, Ardelt M, Dittmar Y, Settmacher U, Rauchfuß F. Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival. World J Gastroenterol 2015;21:12071-82. [PMID: 26576092 DOI: 10.3748/wjg.v21.i42.12071] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
9 Muros-ortega M, Díaz-carrasco M, Vila-clérigues N, Mendoza-otero F, de la Rubia A, Capel Alemán A. Experiencia de uso de partículas DC Bead® cargadas con doxorrubicina en quimioembolización hepática. Farmacia Hospitalaria 2011;35:172-9. [DOI: 10.1016/j.farma.2010.06.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Cillo U, Vitale A, Volk ML, Frigo AC, Grigoletto F, Brolese A, Zanus G, D'Amico F, Farinati F, Burra P, Russo F, Angeli P, D'Amico DF. The survival benefit of liver transplantation in hepatocellular carcinoma patients. Dig Liver Dis 2010;42:642-9. [PMID: 20381438 DOI: 10.1016/j.dld.2010.02.010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
11 Eswaran SL, Pierce K, Weaver F, Rogers T, Brems JJ, Sontag SJ, Borge M. Transarterial chemoembolization for HCC in patients with extensive liver transplantation waiting times. Angiology 2012;63:206-12. [PMID: 21733955 DOI: 10.1177/0003319711411705] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
12 Cools KS, Moon AM, Burke LMB, McGinty KA, Strassle PD, Gerber DA. Validation of the Liver Imaging Reporting and Data System Treatment Response Criteria After Thermal Ablation for Hepatocellular Carcinoma. Liver Transpl 2020;26:203-14. [PMID: 31677319 DOI: 10.1002/lt.25673] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
13 Rudnick SR, Russo MW. Liver transplantation beyond or downstaging within the Milan criteria for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2018;12:265-75. [PMID: 29231769 DOI: 10.1080/17474124.2018.1417035] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
14 Di Costanzo GG, Tortora R. Intermediate hepatocellular carcinoma: How to choose the best treatment modality? World J Hepatol. 2015;7:1184-1191. [PMID: 26019734 DOI: 10.4254/wjh.v7.i9.1184] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
15 Toso C, Mentha G, Majno P. Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence. Am J Transplant. 2011;11:2031-2035. [PMID: 21831154 DOI: 10.1111/j.1600-6143.2011.03689.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 70] [Article Influence: 7.3] [Reference Citation Analysis]
16 Majno P, Mentha G, Toso C; for the Geneva Liver Cancer Study Group. Transplantation for hepatocellular carcinoma: Management of patients on the waiting list. Liver Transpl 2010;16:S2-S11. [DOI: 10.1002/lt.22163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
17 Byrne TJ, Rakela J. Loco-regional therapies for patients with hepatocellular carcinoma awaiting liver transplantation: Selecting an optimal therapy. World J Transplant 2016;6:306-13. [PMID: 27358775 DOI: 10.5500/wjt.v6.i2.306] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
18 Smolock AR, Cristescu MM, Hinshaw A, Woo KM, Wells SA, Ziemlewicz TJ, Lubner MG, Dalvie PS, Louis Hinshaw J, Brace CL. Combination transarterial chemoembolization and microwave ablation improves local tumor control for 3- to 5-cm hepatocellular carcinoma when compared with transarterial chemoembolization alone. Abdom Radiol (NY). 2018;43:2497-2504. [PMID: 29450606 DOI: 10.1007/s00261-018-1464-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
19 Kwong A, Mehta N. Expanding the Limits of Liver Transplantation for Hepatocellular Carcinoma: Is There a Limit? Clin Liver Dis 2021;25:19-33. [PMID: 33978578 DOI: 10.1016/j.cld.2020.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Skagen C, Lucey M, Said A. Liver transplantation: an update 2009: . Current Opinion in Gastroenterology 2009;25:202-8. [DOI: 10.1097/mog.0b013e3283299652] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
21 Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, Mariani L. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl. 2011;17 Suppl 2:S44-S57. [PMID: 21695773 DOI: 10.1002/lt.22365] [Cited by in Crossref: 320] [Cited by in F6Publishing: 265] [Article Influence: 35.6] [Reference Citation Analysis]
22 Kim DJ, Clark PJ, Heimbach J, Rosen C, Sanchez W, Watt K, Charlton MR. Recurrence of hepatocellular carcinoma: importance of mRECIST response to chemoembolization and tumor size. Am J Transplant. 2014;14:1383-1390. [PMID: 24801862 DOI: 10.1111/ajt.12684] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 6.7] [Reference Citation Analysis]
23 Majno P, Giostra E, Mentha G. Management of hepatocellular carcinoma on the waiting list before liver transplantation: Time for controlled trials? Liver Transpl 2007;13:S27-35. [DOI: 10.1002/lt.21328] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
24 Bryce K, Tsochatzis EA. Downstaging for hepatocellular cancer: harm or benefit? Transl Gastroenterol Hepatol. 2017;2:106. [PMID: 29354763 DOI: 10.21037/tgh.2017.11.18] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
25 Kim HD, Shim JH, Kim GA, Shin YM, Yu E, Lee SG, Lee D, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS. Optimal methods for measuring eligibility for liver transplant in hepatocellular carcinoma patients undergoing transarterial chemoembolization. J Hepatol 2015;62:1076-84. [PMID: 25529626 DOI: 10.1016/j.jhep.2014.12.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
26 Pompili M, Francica G, Ponziani FR, Iezzi R, Avolio AW. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. World J Gastroenterol. 2013;19:7515-7530. [PMID: 24282343 DOI: 10.3748/wjg.v19.i43.7515] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 48] [Article Influence: 9.4] [Reference Citation Analysis]
27 Taketomi A, Fukuhara T, Morita K, Kayashima H, Ninomiya M, Yamashita Y, Ikegami T, Uchiyama H, Yoshizumi T, Soejima Y. Improved results of a surgical resection for the recurrence of hepatocellular carcinoma after living donor liver transplantation. Ann Surg Oncol. 2010;17:2283-2289. [PMID: 20204531 DOI: 10.1245/s10434-010-0999-y] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
28 Cescon M, Cucchetti A, Ravaioli M, Pinna AD. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. J Hepatol. 2013;58:609-618. [PMID: 23041304 DOI: 10.1016/j.jhep.2012.09.021] [Cited by in Crossref: 99] [Cited by in F6Publishing: 80] [Article Influence: 11.0] [Reference Citation Analysis]
29 Zarrinpar A, Kaldas F, Busuttil RW. Liver transplantation for hepatocellular carcinoma: an update. Hepatobiliary & Pancreatic Diseases International 2011;10:234-42. [DOI: 10.1016/s1499-3872(11)60039-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
30 Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, Roberts J, Reich DJ, Schwartz ME, Mieles L, Lee FT, Florman S, Yao F, Harper A, Edwards E, Freeman R, Lake J. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States: Liver Allocation in Patients With HCC. Liver Transpl 2010;16:262-78. [DOI: 10.1002/lt.21999] [Cited by in Crossref: 293] [Cited by in F6Publishing: 223] [Article Influence: 24.4] [Reference Citation Analysis]
31 Iavarone M, Colombo M. HBV-related HCC, clinical issues and therapy. Dig Liver Dis. 2011;43 Suppl 1:S32-S39. [PMID: 21195370 DOI: 10.1016/S1590-8658(10)60690-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
32 Yao FY, Kerlan RK Jr, Hirose R, Davern TJ 3rd, Bass NM, Feng S, Peters M, Terrault N, Freise CE, Ascher NL, Roberts JP. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology. 2008;48:819-827. [PMID: 18688876 DOI: 10.1002/hep.22412] [Cited by in Crossref: 355] [Cited by in F6Publishing: 288] [Article Influence: 27.3] [Reference Citation Analysis]
33 Lu DS, Siripongsakun S, Kyong Lee J, Wei SH, Cheng PM, Sabounchi S, Lee JS, Raman S, Tong MJ, Busuttil RW, Sayre J. Complete tumor encapsulation on magnetic resonance imaging: A potentially useful imaging biomarker for better survival in solitary large hepatocellular carcinoma: Complete Tumor Encapsulation. Liver Transpl 2013;19:283-91. [DOI: 10.1002/lt.23597] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
34 Bouchard-Fortier A, Lapointe R, Perreault P, Bouchard L, Pomier-Layrargues G. Transcatheter arterial chemoembolization of hepatocellular carcinoma as a bridge to liver transplantation: a retrospective study. Int J Hepatol. 2011;2011:974514. [PMID: 21994880 DOI: 10.4061/2011/974514] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
35 Taketomi A, Soejima Y, Yoshizumi T, Uchiyama H, Yamashita Y, Maehara Y. Liver transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2008;15:124-30. [DOI: 10.1007/s00534-007-1296-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
36 Dufour JF, Johnson P. Liver cancer: from molecular pathogenesis to new therapies: summary of the EASL single topic conference. J Hepatol 2010;52:296-304. [PMID: 20006399 DOI: 10.1016/j.jhep.2009.11.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
37 Lei J, Wang W, Yan L. Surgical resection versus open-approach radiofrequency ablation for small hepatocellular carcinomas within Milan criteria after successful transcatheter arterial chemoembolization. J Gastrointest Surg 2013;17:1752-9. [PMID: 23959694 DOI: 10.1007/s11605-013-2311-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
38 Sandow T, Pavlus J, Field D, Lacayo E, Cohen E, Lynskey G, Caridi T, Buckley D, Cardella J, Kallakury B, Spies J, Kim AY. Bridging Hepatocellular Carcinoma to Transplant: Transarterial Chemoembolization Response, Tumor Biology, and Recurrence after Transplantation in a 12-Year Transplant Cohort. J Vasc Interv Radiol 2019;30:995-1003. [PMID: 31109853 DOI: 10.1016/j.jvir.2018.12.736] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
39 Woo HY, Jang JW, Choi JY, You CR, Jeong SW, Bae SH, Yoon SK, Lee YS, Kim DG. Living donor liver transplantation in hepatocellular carcinoma beyond the Milan criteria. Liver Int. 2008;28:1120-1128. [PMID: 18492023 DOI: 10.1111/j.1478-3231.2008.01785.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
40 Padma S, Martinie JB, Iannitti DA. Liver tumor ablation: Percutaneous and open approaches. J Surg Oncol. 2009;100:619-634. [PMID: 20017157 DOI: 10.1002/jso.21364] [Cited by in Crossref: 68] [Cited by in F6Publishing: 51] [Article Influence: 6.2] [Reference Citation Analysis]
41 Ho M, Yu C, Chung K, Chen T, Chu H, Lin C, Hsieh C. Locoregional Therapy-Induced Tumor Necrosis as a Predictor of Recurrence after Liver Transplant in Patients with Hepatocellular Carcinoma. Ann Surg Oncol 2011;18:3632-9. [DOI: 10.1245/s10434-011-1803-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
42 Li K, Neuberger J. The management of patients awaiting liver transplantation. Nat Rev Gastroenterol Hepatol 2009;6:648-59. [DOI: 10.1038/nrgastro.2009.163] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
43 Sandhu DS, Tharayil VS, Lai JP, Roberts LR. Treatment options for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2008;2:81-92. [PMID: 19072372 DOI: 10.1586/17474124.2.1.81] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
44 Liang L, Xing H, Zhang H, Zhong J, Li C, Lau WY, Wu M, Shen F, Yang T. Surgical resection vs transarterial chemoembolization for BCLC intermediate stage hepatocellular carcinoma: a systematic review and meta-analysis. HPB (Oxford). 2018;20:110-119. [PMID: 29174493 DOI: 10.1016/j.hpb.2017.10.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
45 Park SJ, Freise CE, Hirose R, Kerlan RK, Yao FY, Roberts JP, Vagefi PA. Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma. Clin Transplant. 2012;26:E359-E364. [PMID: 22693962 DOI: 10.1111/j.1399-0012.2012.01668.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
46 Schmitt TM, Kumer SC, Shah N, Argo CK, Northup PG. Liver transplantation for T3 lesions has higher waiting list mortality but similar survival compared to T1 and T2 lesions. Annals of Hepatology 2010;9:390-6. [DOI: 10.1016/s1665-2681(19)31614-x] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
47 Kollmann D, Selzner N, Selzner M. Bridging to liver transplantation in HCC patients. Langenbecks Arch Surg. 2017;402:863-871. [PMID: 28755240 DOI: 10.1007/s00423-017-1609-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
48 Majno P, Lencioni R, Mornex F, Girard N, Poon RT, Cherqui D. Is the treatment of hepatocellular carcinoma on the waiting list necessary? Liver Transpl. 2011;17 Suppl 2:S98-108. [PMID: 21954097 DOI: 10.1002/lt.22391] [Cited by in Crossref: 51] [Cited by in F6Publishing: 40] [Article Influence: 5.7] [Reference Citation Analysis]
49 Kornberg A, Witt U, Matevossian E, Küpper B, Assfalg V, Drzezga A, Hüser N, Wildgruber M, Friess H. Extended postinterventional tumor necrosis-implication for outcome in liver transplant patients with advanced HCC. PLoS One. 2013;8:e53960. [PMID: 23349774 DOI: 10.1371/journal.pone.0053960] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
50 Decaens T, Hurtova M, Duvoux C. Transplantation hépatique pour carcinome hépatocellulaire. Gastroentérologie Clinique et Biologique 2009;33:61-9. [DOI: 10.1016/j.gcb.2008.11.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
51 Agopian VG, Harlander-Locke MP, Ruiz RM, Klintmalm GB, Senguttuvan S, Florman SS, Haydel B, Hoteit M, Levine MH, Lee DD, Taner CB, Verna EC, Halazun KJ, Abdelmessih R, Tevar AD, Humar A, Aucejo F, Chapman WC, Vachharajani N, Nguyen MH, Melcher ML, Nydam TL, Mobley C, Ghobrial RM, Amundsen B, Markmann JF, Langnas AN, Carney CA, Berumen J, Hemming AW, Sudan DL, Hong JC, Kim J, Zimmerman MA, Rana A, Kueht ML, Jones CM, Fishbein TM, Busuttil RW. Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium. Ann Surg. 2017;266:525-535. [PMID: 28654545 DOI: 10.1097/sla.0000000000002381] [Cited by in Crossref: 63] [Cited by in F6Publishing: 27] [Article Influence: 15.8] [Reference Citation Analysis]
52 Dioguardi Burgio M, Sartoris R, Libotean C, Zappa M, Sibert A, Vilgrain V, Ronot M. Lipiodol retention pattern after TACE for HCC is a predictor for local progression in lesions with complete response. Cancer Imaging 2019;19:75. [PMID: 31730491 DOI: 10.1186/s40644-019-0260-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
53 Masuoka HC, Rosen CB. Liver Transplantation for Hepatocellular Carcinoma: Expanding Frontiers and Building Bridges. Clinics in Liver Disease 2011;15:385-93. [DOI: 10.1016/j.cld.2011.03.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
54 Lysy PA, Smets F, Sibille C, Najimi M, Sokal EM. Human skin fibroblasts: From mesodermal to hepatocyte-like differentiation. Hepatology. 2007;46:1574-1585. [PMID: 17969047 DOI: 10.1002/hep.28139] [Cited by in Crossref: 82] [Cited by in F6Publishing: 58] [Article Influence: 5.9] [Reference Citation Analysis]
55 Salvalaggio PR, Felga GE, Guardia BD, Almeida MD, Pandullo FL, Matielo CE, Evangelista A, Curvelo L, Rocco RA, Alves JA, Meirelles RF Jr, Filho SP, de Rezende MB, Pedroso PT, Diaz LG, Rusi MB, Viveiros MM, Neves DB. Time of Dropout From the Liver Transplant List in Patients With Hepatocellular Carcinoma: Clinical Behavior According to Tumor Characteristics and Severity of Liver Disease. Transplant Proc 2016;48:2319-22. [PMID: 27742288 DOI: 10.1016/j.transproceed.2016.06.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
56 Cucchetti A, Cescon M, Bigonzi E, Piscaglia F, Golfieri R, Ercolani G, Cristina Morelli M, Ravaioli M, Daniele Pinna A. Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy. Liver Transpl. 2011;17:1344-1354. [PMID: 21837731 DOI: 10.1002/lt.22397] [Cited by in Crossref: 67] [Cited by in F6Publishing: 58] [Article Influence: 7.4] [Reference Citation Analysis]
57 Cillo U, Giuliani T, Polacco M, Herrero Manley LM, Crivellari G, Vitale A. Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World J Gastroenterol. 2016;22:232-252. [PMID: 26755873 DOI: 10.3748/wjg.v22.i1.232] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
58 Montalti R, Mimmo A, Rompianesi G, Di Gregorio C, Serra V, Cautero N, Ballarin R, Spaggiari M, Tarantino G, D'Amico G, De Santis M, De Pietri L, Troisi RI, Gerunda GE, Di Benedetto F. Absence of viable HCC in the native liver is an independent protective factor of tumor recurrence after liver transplantation. Transplantation 2014;97:220-6. [PMID: 24056629 DOI: 10.1097/TP.0b013e3182a8607e] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
59 Lai Q, Avolio AW, Graziadei I, Otto G, Rossi M, Tisone G, Goffette P, Vogel W, Pitton MB, Lerut J; on behalf of the European Hepatocellular Cancer Liver Transplant Study Group. Alpha-fetoprotein and modified response evaluation criteria in Solid Tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation: Alpha-Fetoprotein Increase and m RECIST Progression. Liver Transpl 2013;19:1108-18. [DOI: 10.1002/lt.23706] [Cited by in Crossref: 121] [Cited by in F6Publishing: 107] [Article Influence: 15.1] [Reference Citation Analysis]
60 Kobayashi T, Ishiyama K, Ohdan H. Prevention of recurrence after curative treatment for hepatocellular carcinoma. Surg Today 2013;43:1347-54. [DOI: 10.1007/s00595-012-0473-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
61 Tsochatzis E, Garcovich M, Marelli L, Papastergiou V, Fatourou E, Rodriguez-Peralvarez ML, Germani G, Davies N, Yu D, Luong TV, Dhillon AP, Thorburn D, Patch D, O'Beirne J, Meyer T, Burroughs AK. Transarterial embolization as neo-adjuvant therapy pretransplantation in patients with hepatocellular carcinoma. Liver Int. 2013;33:944-949. [PMID: 23530918 DOI: 10.1111/liv.12144] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
62 Lei J, Wang W, Yan L. Downstaging Advanced Hepatocellular Carcinoma to the Milan Criteria May Provide a Comparable Outcome to Conventional Milan Criteria. J Gastrointest Surg 2013;17:1440-6. [DOI: 10.1007/s11605-013-2229-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
63 Heinzow HS, Meister T, Nass D, Köhler M, Spieker T, Wolters H, Domschke W, Domagk D. Outcome of supraselective transarterial chemoembolization in patients with hepatocellular carcinoma. Scand J Gastroenterol 2011;46:201-10. [PMID: 20969491 DOI: 10.3109/00365521.2010.525256] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
64 Roberts JP, Venook A, Kerlan R, Yao F. Hepatocellular carcinoma: Ablate and wait versus rapid transplantation. Liver Transpl. 2010;16:925-929. [PMID: 20658555 DOI: 10.1002/lt.22103] [Cited by in Crossref: 99] [Cited by in F6Publishing: 87] [Article Influence: 9.0] [Reference Citation Analysis]
65 Miraglia R, Pietrosi G, Maruzzelli L, Petridis I, Caruso S, Marrone G, Mamone G, Vizzini G, Luca A, Gridelli B. Predictive factors of tumor response to trans-catheter treatment in cirrhotic patients with hepatocellular carcinoma: a multivariate analysis of pre-treatment findings. World J Gastroenterol 2007;13:6022-6. [PMID: 18023093 DOI: 10.3748/wjg.v13.45.6022] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
66 Luo J, Peng ZW, Guo RP, Zhang YQ, Li JQ, Chen MS, Shi M. Hepatic resection versus transarterial lipiodol chemoembolization as the initial treatment for large, multiple, and resectable hepatocellular carcinomas: a prospective nonrandomized analysis. Radiology. 2011;259:286-295. [PMID: 21330557 DOI: 10.1148/radiol.10101072] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
67 Guerrero-Misas M, Rodríguez-Perálvarez M, De la Mata M. Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation. World J Hepatol 2015;7:649-61. [PMID: 25866602 DOI: 10.4254/wjh.v7.i4.649] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
68 Mehta N, Yao FY. Hepatocellular cancer as indication for liver transplantation: pushing beyond Milan. Current Opinion in Organ Transplantation 2016;21:91-8. [DOI: 10.1097/mot.0000000000000282] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 2.6] [Reference Citation Analysis]
69 Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant. 2008;8:1982-1989. [PMID: 18727702 DOI: 10.1111/j.1600-6143.2008.02351.x] [Cited by in Crossref: 132] [Cited by in F6Publishing: 112] [Article Influence: 10.2] [Reference Citation Analysis]
70 Vivarelli M, Risaliti A. Liver transplantation for hepatocellular carcinoma on cirrhosis: strategies to avoid tumor recurrence. World J Gastroenterol. 2011;17:4741-4746. [PMID: 22147974 DOI: 10.3748/wjg.v17.i43.4741] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
71 Sinha J, Mehta N, Dodge JL, Poltavskiy E, Roberts J, Yao F. Are There Upper Limits in Tumor Burden for Down‐Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All‐Comers Protocol. Hepatology 2019;70:1185-96. [DOI: 10.1002/hep.30570] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
72 Alhamad A, Hassanain M, Michel RP, Metrakos P, Roberge D. Stereotactic Radiotherapy of the Liver: A Bridge to Transplantation. Technol Cancer Res Treat 2009;8:401-5. [DOI: 10.1177/153303460900800601] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
73 Washburn K, Halff G. Hepatocellular carcinoma and liver transplantation. Curr Opin Organ Transplant. 2011;16:297-300. [PMID: 21505342 DOI: 10.1097/mot.0b013e3283465756] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
74 Na GH, Kim EY, Hong TH, You YK, Kim DG. Effects of loco regional treatments before living donor liver transplantation on overall survival and recurrence-free survival in South Korean patients with hepatocellular carcinoma. HPB (Oxford). 2016;18:98-106. [PMID: 26776857 DOI: 10.1016/j.hpb.2015.08.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
75 Chang Y, Jeong SW, Young Jang J, Jae Kim Y. Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E8165. [PMID: 33142892 DOI: 10.3390/ijms21218165] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
76 Li HL, Ji WB, Zhao R, Duan WD, Chen YW, Wang XQ, Yu Q, Luo Y, Dong JH. Poor prognosis for hepatocellular carcinoma with transarterial chemoembolization pre-transplantation: retrospective analysis. World J Gastroenterol. 2015;21:3599-3606. [PMID: 25834326 DOI: 10.3748/wjg.v21.i12.3599] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
77 Sourianarayanane A, El-Gazzaz G, Sanabria JR, Menon KV, Quintini C, Hashimoto K, Kelly D, Eghtesad B, Miller C, Fung J, Aucejo F. Loco-regional therapy in patients with Milan Criteria-compliant hepatocellular carcinoma and short waitlist time to transplant: An outcome analysis. HPB (Oxford). 2012;14:325-332. [PMID: 22487070 DOI: 10.1111/j.1477-2574.2012.00453.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
78 Mehta N, Dodge JL, Grab JD, Yao FY. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time. Hepatology 2020;71:943-54. [PMID: 31344273 DOI: 10.1002/hep.30879] [Cited by in Crossref: 41] [Cited by in F6Publishing: 28] [Article Influence: 20.5] [Reference Citation Analysis]
79 Frangakis C, Geschwind JF, Kim D, Chen Y, Koteish A, Hong K, Liapi E, Georgiades CS. Chemoembolization decreases drop-off risk of hepatocellular carcinoma patients on the liver transplant list. Cardiovasc Intervent Radiol. 2011;34:1254-1261. [PMID: 21191590 DOI: 10.1007/s00270-010-0077-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
80 Merani S, Majno P, Kneteman NM, Berney T, Morel P, Mentha G, Toso C. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol. 2011;55:814-819. [PMID: 21334400 DOI: 10.1016/j.jhep.2010.12.040] [Cited by in Crossref: 119] [Cited by in F6Publishing: 102] [Article Influence: 11.9] [Reference Citation Analysis]
81 Finkenstedt A, Vikoler A, Portenkirchner M, Mülleder K, Maglione M, Margreiter C, Moser P, Vogel W, Bale R, Freund M, Luger A, Tilg H, Petersen J, Schneeberger S, Graziadei I, Zoller H, Glodny B. Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy. Liver Int 2016;36:688-95. [PMID: 26386273 DOI: 10.1111/liv.12966] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
82 Silva MF, Wigg AJ. Current controversies surrounding liver transplantation for hepatocellular carcinoma. J Gastroenterol Hepatol. 2010;25:1217-1226. [PMID: 20594247 DOI: 10.1111/j.1440-1746.2010.06335.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
83 Hodavance MS, Vikingstad EM, Griffin AS, Pabon-ramos WM, Berg CL, Suhocki PV, Kim CY. Effectiveness of Transarterial Embolization of Hepatocellular Carcinoma as a Bridge to Transplantation. Journal of Vascular and Interventional Radiology 2016;27:39-45. [DOI: 10.1016/j.jvir.2015.08.032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
84 Györi GP, Felsenreich DM, Silberhumer GR, Soliman T, Berlakovich GA. Multimodality locoregional treatment strategies for bridging HCC patients before liver transplantation. Eur Surg 2017;49:236-43. [PMID: 29104589 DOI: 10.1007/s10353-017-0487-8] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
85 Uemura T, Kirichenko A, Bunker M, Vincent M, Machado L, Thai N. Stereotactic Body Radiation Therapy: A New Strategy for Loco-Regional Treatment for Hepatocellular Carcinoma While Awaiting Liver Transplantation. World J Surg 2019;43:886-93. [PMID: 30361748 DOI: 10.1007/s00268-018-4829-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
86 Jang JW, You CR, Kim CW, Bae SH, Yoon SK, Yoo YK, Kim DG, Choi JY. Benefit of downsizing hepatocellular carcinoma in a liver transplant population. Aliment Pharmacol Ther. 2010;31:415-423. [PMID: 19821808 DOI: 10.1111/j.1365-2036.2009.04167.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 47] [Article Influence: 4.8] [Reference Citation Analysis]
87 Kapitanov T, Neumann UP, Schmeding M. Hepatocellular Carcinoma in Liver Cirrhosis: Surgical Resection versus Transarterial Chemoembolization-A Meta-Analysis. Gastroenterol Res Pract 2015;2015:696120. [PMID: 25642245 DOI: 10.1155/2015/696120] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
88 Vitale A, D’Amico F, Frigo AC, Grigoletto F, Brolese A, Zanus G, Neri D, Carraro A, D’Amico FE, Burra P. Response to therapy as a criterion for awarding priority to patients with hepatocellular carcinoma awaiting liver transplantation. Ann Surg Oncol. 2010;17:2290-2302. [PMID: 20217249 DOI: 10.1245/s10434-010-0993-4] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
89 Hanje AJ, Yao FY. Current approach to down-staging of hepatocellular carcinoma prior to liver transplantation. Curr Opin Organ Transplant 2008;13:234-40. [PMID: 18685309 DOI: 10.1097/MOT.0b013e3282fc2633] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
90 El-Gazzaz G, Sourianarayanane A, Menon KVN, Sanabria J, Hashimoto K, Quintini C, Kelly D, Eghtesad B, Miller C, Fung J. Radiologic-histological correlation of hepatocellular carcinoma treated via pre-liver transplant locoregional therapies. Hepatobiliary & Pancreatic Diseases International. 2013;12:34-41. [PMID: 23392796 DOI: 10.1016/s1499-3872(13)60003-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
91 Zhou B, Shan H, Zhu KS, Jiang ZB, Guan SH, Meng XC, Zeng XC. Chemoembolization with lobaplatin mixed with iodized oil for unresectable recurrent hepatocellular carcinoma after orthotopic liver transplantation. J Vasc Interv Radiol. 2010;21:333-338. [PMID: 20116286 DOI: 10.1016/j.jvir.2009.11.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
92 Ziogas IA, Hickman LA, Matsuoka LK, Izzy M, Montenovo MI, Rega SA, Feurer ID, Alexopoulos SP. Comparison of Wait-List Mortality Between Cholangiocarcinoma and Hepatocellular Carcinoma Liver Transplant Candidates. Liver Transpl. 2020;26:1112-1120. [PMID: 32475062 DOI: 10.1002/lt.25807] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
93 Dendy MS, Camacho JC, Ludwig JM, Krasinskas AM, Knechtle SJ, Kim HS. Infiltrative Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis Treated With a Single High-Dose Y90 Radioembolization and Subsequent Liver Transplantation Without a Recurrence. Transplant Direct 2017;3:e206. [PMID: 28894793 DOI: 10.1097/TXD.0000000000000707] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
94 San Miguel C, Muffak K, Triguero J, Becerra A, Villegas T, Nogueras F, Expósito M, Fundora Y. Role of Transarterial Chemoembolization to Downstage Hepatocellular Carcinoma Within the Milan Criteria. Transplantation Proceedings 2015;47:2631-3. [DOI: 10.1016/j.transproceed.2015.10.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
95 Unzueta A, Cabrera R. Treatment Options in Patients Awaiting Liver Transplantation with Hepatocellular Carcinoma and Cholangiocarcinoma. Clinics in Liver Disease 2017;21:231-51. [DOI: 10.1016/j.cld.2016.12.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
96 Wedd JP, Nordstrom E, Nydam T, Durham J, Zimmerman M, Johnson T, Thomas Purcell W, Biggins SW. Hepatocellular carcinoma in patients listed for liver transplantation: Current and future allocation policy and management strategies for the individual patient. Liver Transpl. 2015;21:1543-1552. [PMID: 26457885 DOI: 10.1002/lt.24356] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
97 Hoffmann K, Hinz U, Hillebrand N, Radeleff BA, Ganten TM, Schirmacher P, Schmidt J, Büchler MW, Schemmer P. Risk factors of survival after liver transplantation for HCC: a multivariate single-center analysis. Clin Transplant 2011;25:E541-51. [PMID: 21518002 DOI: 10.1111/j.1399-0012.2011.01465.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
98 Lee DD, Samoylova M, Mehta N, Musto KR, Roberts JP, Yao FY, Harnois DM. The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. Liver Transpl 2019;25:228-41. [DOI: 10.1002/lt.25333] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
99 Washburn K, Edwards E, Harper A, Freeman R. Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transplant. 2010;10:1643-1648. [PMID: 20486906 DOI: 10.1111/j.1600-6143.2010.03127.x] [Cited by in Crossref: 175] [Cited by in F6Publishing: 145] [Article Influence: 15.9] [Reference Citation Analysis]
100 Agopian VG, Morshedi MM, Mcwilliams J, Harlander-locke MP, Markovic D, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, Hiatt JR, Busuttil RW. Complete Pathologic Response to Pretransplant Locoregional Therapy for Hepatocellular Carcinoma Defines Cancer Cure After Liver Transplantation: Analysis of 501 Consecutively Treated Patients. Annals of Surgery 2015;262:536-45. [DOI: 10.1097/sla.0000000000001384] [Cited by in Crossref: 69] [Cited by in F6Publishing: 33] [Article Influence: 11.5] [Reference Citation Analysis]
101 Lee MW, Raman SS, Asvadi NH, Siripongsakun S, Hicks RM, Chen J, Worakitsitisatorn A, Mcwilliams J, Tong MJ, Finn RS, Agopian VG, Busuttil RW, Lu DS. Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10-year intention-to-treat analysis. Hepatology 2017;65:1979-90. [DOI: 10.1002/hep.29098] [Cited by in Crossref: 51] [Cited by in F6Publishing: 39] [Article Influence: 12.8] [Reference Citation Analysis]
102 Paik KY, Kim EK. Pathologic response to preoperative transarterial chemoembolization for resectable hepatocellular carcinoma may not predict recurrence after liver resection. Hepatobiliary & Pancreatic Diseases International 2016;15:158-64. [DOI: 10.1016/s1499-3872(15)60042-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
103 Wang ZY, Geng L, Zheng SS. Current strategies for preventing the recurrence of hepatocellular carcinoma after liver transplantation. Hepatobiliary Pancreat Dis Int 2015;14:145-9. [PMID: 25865686 DOI: 10.1016/s1499-3872(15)60345-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
104 de Villa V, Lo CM. Liver transplantation for hepatocellular carcinoma in Asia. Oncologist. 2007;12:1321-1331. [PMID: 18055852 DOI: 10.1634/theoncologist.12-11-1321] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 6.2] [Reference Citation Analysis]
105 Sommer CM, Stampfl U, Kauczor HU, Pereira PL. [National S3 guidelines on hepatocellular carcinoma]. Radiologe 2014;54:642-53. [PMID: 25047521 DOI: 10.1007/s00117-014-2656-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
106 Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, Salgia R, Seetharam A, Sharma P, Sherman C, Tsoulfas G, Yao FY. Liver transplantation for hepatocellular carcinoma: Management after the transplant. Am J Transplant 2020;20:333-47. [PMID: 31710773 DOI: 10.1111/ajt.15697] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
107 Rossetto A, Adani GL, Baccarani U, Bresadola V, Lorenzin D, Sponza M, Vit A, De Anna D, Bresadola F. Necrosis percentage of radiologically treated hepatocellular carcinoma at hepatectomy for liver transplantation. Transplant Proc 2011;43:1095-7. [PMID: 21620061 DOI: 10.1016/j.transproceed.2011.01.151] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
108 Cabrera R, Dhanasekaran R, Caridi J, Clark V, Morelli G, Soldevila-Pico C, Magglioca J, Nelson D, Firpi RJ. Impact of transarterial therapy in hepatitis C-related hepatocellular carcinoma on long-term outcomes after liver transplantation. Am J Clin Oncol 2012;35:345-50. [PMID: 21552101 DOI: 10.1097/COC.0b013e31821631f6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
109 Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev 2019;72:28-36. [PMID: 30447470 DOI: 10.1016/j.ctrv.2018.11.002] [Cited by in Crossref: 72] [Cited by in F6Publishing: 60] [Article Influence: 24.0] [Reference Citation Analysis]
110 Fujiki M, Aucejo F, Kim R. General overview of neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: necessity or option? Liver Int. 2011;31:1081-1089. [PMID: 22008644 DOI: 10.1111/j.1478-3231.2011.02473.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
111 Tan H, Martin P. Care of the Liver Transplant Candidate. Clinics in Liver Disease 2011;15:779-806. [DOI: 10.1016/j.cld.2011.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
112 Washburn K. Model for End Stage Liver Disease and hepatocellular carcinoma: a moving target. Transplant Rev (Orlando). 2010;24:11-17. [PMID: 19942101 DOI: 10.1016/j.trre.2009.10.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
113 Yao FY, Breitenstein S, Broelsch CE, Dufour JF, Sherman M. Does a patient qualify for liver transplantation after the down-staging of hepatocellular carcinoma? Liver Transpl. 2011;17 Suppl 2:S109-S116. [PMID: 21584927 DOI: 10.1002/lt.22335] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
114 Mehta N, Bhangui P, Yao FY, Mazzaferro V, Toso C, Akamatsu N, Durand F, Ijzermans J, Polak W, Zheng S, Roberts JP, Sapisochin G, Hibi T, Kwan NM, Ghobrial M, Soin A. Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation 2020;104:1136-42. [DOI: 10.1097/tp.0000000000003174] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 16.0] [Reference Citation Analysis]
115 Toso C, Mentha G, Kneteman NM, Majno P. The place of downstaging for hepatocellular carcinoma. J Hepatol. 2010;52:930-936. [PMID: 20385428 DOI: 10.1016/j.jhep.2009.12.032] [Cited by in Crossref: 88] [Cited by in F6Publishing: 74] [Article Influence: 8.0] [Reference Citation Analysis]
116 Agopian VG, Harlander-Locke M, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, Finn RS, Tong M, Hiatt JR, Busuttil RW. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. J Am Coll Surg. 2015;220:416-427. [PMID: 25690672 DOI: 10.1016/j.jamcollsurg.2014.12.025] [Cited by in Crossref: 132] [Cited by in F6Publishing: 108] [Article Influence: 18.9] [Reference Citation Analysis]
117 Katz AW, Chawla S, Qu Z, Kashyap R, Milano MT, Hezel AF. Stereotactic Hypofractionated Radiation Therapy as a Bridge to Transplantation for Hepatocellular Carcinoma: Clinical Outcome and Pathologic Correlation. International Journal of Radiation Oncology*Biology*Physics 2012;83:895-900. [DOI: 10.1016/j.ijrobp.2011.08.032] [Cited by in Crossref: 65] [Cited by in F6Publishing: 52] [Article Influence: 7.2] [Reference Citation Analysis]
118 Salvalaggio PR, Felga G, Axelrod DA, Della Guardia B, Almeida MD, Rezende MB. List and Liver Transplant Survival According to Waiting Time in Patients With Hepatocellular Carcinoma: Time on the List and Survival in HCC Recipients. American Journal of Transplantation 2015;15:668-77. [DOI: 10.1111/ajt.13011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
119 Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl. 2014;20:945-951. [PMID: 24797281 DOI: 10.1002/lt.23904] [Cited by in Crossref: 145] [Cited by in F6Publishing: 122] [Article Influence: 20.7] [Reference Citation Analysis]
120 Graziadei I, Zoller H, Fickert P, Schneeberger S, Finkenstedt A, Peck-Radosavljevic M, Müller H, Kohl C, Sperner-Unterweger B, Eschertzhuber S, Hofer H, Öfner D, Tilg H, Vogel W, Trauner M, Berlakovich G. Indications for liver transplantation in adults : Recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX). Wien Klin Wochenschr 2016;128:679-90. [PMID: 27590261 DOI: 10.1007/s00508-016-1046-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
121 Koschny R, Schmidt J, Ganten TM. Beyond Milan criteria--chances and risks of expanding transplantation criteria for HCC patients with liver cirrhosis. Clin Transplant 2009;23 Suppl 21:49-60. [PMID: 19930317 DOI: 10.1111/j.1399-0012.2009.01110.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
122 Akoad ME, Pomfret EA. Surgical Resection and Liver Transplantation for Hepatocellular Carcinoma. Clinics in Liver Disease 2015;19:381-99. [DOI: 10.1016/j.cld.2015.01.007] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
123 Kornberg A. Liver transplantation for hepatocellular carcinoma beyond Milan criteria: multidisciplinary approach to improve outcome. ISRN Hepatol. 2014;25:154-159. [PMID: 27335840 DOI: 10.1155/2014/706945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
124 Fujiki M, Aucejo F, Choi M, Kim R. Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: where do we stand? World J Gastroenterol. 2014;20:5308-5319. [PMID: 24833861 DOI: 10.3748/wjg.v20.i18.5308] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
125 Said A, Lucey MR. Liver transplantation: an update 2008. Curr Opin Gastroenterol. 2008;24:339-345. [PMID: 18408462 DOI: 10.1097/mog.0b013e3282f8e27e] [Cited by in Crossref: 27] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
126 Lei J, Zhong J, Luo Y, Yan L, Zhu J, Wang W, Li B, Wen T, Yang J; Liver Surgery Group. Response to transarterial chemoembolization may serve as selection criteria for hepatocellular carcinoma liver transplantation. Oncotarget 2017;8:91328-42. [PMID: 29207647 DOI: 10.18632/oncotarget.20511] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
127 Soriano A, Varona A, Gianchandani R, Moneva ME, Arranz J, Gonzalez A, Barrera M. Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future. World J Hepatol 2016;8:58-68. [PMID: 26783421 DOI: 10.4254/wjh.v8.i1.58] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
128 Eguchi S, Hidaka M, Tomonaga T, Miyazaki K, Inokuma T, Takatsuki M, Okudaira S, Yamanouchi K, Miyaaki H, Ichikawa T, Tajima Y, Kanematsu T. Actual therapeutic efficacy of pre-transplant treatment on hepatocellular carcinoma and its impact on survival after salvage living donor liver transplantation. J Gastroenterol 2009;44:624-9. [PMID: 19381752 DOI: 10.1007/s00535-009-0043-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
129 Minici R, Ammendola M, Manti F, Siciliano MA, Giglio E, Minici M, Melina M, Currò G, Laganà D. Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization as a Bridging Therapy in Patients with Early Stage Hepatocellular Carcinoma and Child-Pugh Stage B Eligible for Liver Transplant. Front Pharmacol 2021;12:634084. [PMID: 33897421 DOI: 10.3389/fphar.2021.634084] [Reference Citation Analysis]
130 Pavel MC, Fuster J. Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions. World J Gastroenterol 2018;24:3626-36. [PMID: 30166858 DOI: 10.3748/wjg.v24.i32.3626] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
131 Hakeem AR, Young RS, Marangoni G, Lodge JP, Prasad KR. Systematic review: the prognostic role of alpha-fetoprotein following liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2012;35:987-999. [PMID: 22429190 DOI: 10.1111/j.1365-2036.2012.05060.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 39] [Article Influence: 1.9] [Reference Citation Analysis]
132 Wu TH, Wang YC, Cheng CH, Lee CF, Wu TJ, Chou HS, Chan KM, Lee WC. Outcomes associated with the intention of loco-regional therapy prior to living donor liver transplantation for hepatocellular carcinoma. World J Gastrointest Surg 2020;12:17-27. [PMID: 31984121 DOI: 10.4240/wjgs.v12.i1.17] [Reference Citation Analysis]
133 Yeh MM, Yeung RS, Apisarnthanarax S, Bhattacharya R, Cuevas C, Harris WP, Hon TL, Padia SA, Park JO, Riggle KM, Daoud SS. Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience. World J Hepatol 2015;7:1460-83. [PMID: 26085907 DOI: 10.4254/wjh.v7.i11.1460] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
134 Said A, Einstein M, Lucey MR. Liver transplantation: an update 2007: . Current Opinion in Gastroenterology 2007;23:292-8. [DOI: 10.1097/mog.0b013e3280f9df41] [Cited by in Crossref: 17] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
135 Pompili M, Pacella CM, Francica G, Angelico M, Tisone G, Craboledda P, Nicolardi E, Rapaccini GL, Gasbarrini G. Percutaneous laser ablation of hepatocellular carcinoma in patients with liver cirrhosis awaiting liver transplantation. Eur J Radiol. 2010;74:e6-e11. [PMID: 19345541 DOI: 10.1016/j.ejrad.2009.03.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
136 Salvalaggio P, Felga G, Alves J, Meirelles R, Almeida M, de Rezende M. Response to Transarterial Chemoembolization in Candidates With Hepatocellular Carcinoma Within Milan Criteria Does not Predict Post-Transplant Disease-Free Survival. Transplantation Proceedings 2014;46:1799-802. [DOI: 10.1016/j.transproceed.2014.05.039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
137 Pompili M, Francica G, Rapaccini GL. Bridge treatments of hepatocellular carcinoma in cirrhotic patients submitted to liver transplantation. Dig Dis Sci 2008;53:2830-1. [PMID: 18716875 DOI: 10.1007/s10620-008-0435-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
138 Schlansky B, Chen Y, Scott DL, Austin D, Naugler WE. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry. Liver Transpl. 2014;20:1045-1056. [PMID: 24838471 DOI: 10.1002/lt.23917] [Cited by in Crossref: 59] [Cited by in F6Publishing: 44] [Article Influence: 8.4] [Reference Citation Analysis]
139 Sharr WW, Chan SC, Lo CM. Section 3. Current status of downstaging of hepatocellular carcinoma before liver transplantation. Transplantation. 2014;97 Suppl 8:S10-S17. [PMID: 24849822 DOI: 10.1097/01.tp.0000446267.19148.21] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
140 Bhoori S, Sposito C, Germini A, Coppa J, Mazzaferro V. The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis. Transpl Int. 2010;23:712-722. [PMID: 20492616 DOI: 10.1111/j.1432-2277.2010.01111.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
141 Otto G, Schuchmann M, Hoppe-lotichius M, Heise M, Weinmann A, Hansen T, Pitton MP. How to decide about liver transplantation in patients with hepatocellular carcinoma: Size and number of lesions or response to TACE? Journal of Hepatology 2013;59:279-84. [DOI: 10.1016/j.jhep.2013.04.006] [Cited by in Crossref: 75] [Cited by in F6Publishing: 69] [Article Influence: 9.4] [Reference Citation Analysis]
142 Macdonald B, Sewell JL, Harper AM, Roberts JP, Yao FY. Liver transplantation for hepatocellular carcinoma: analysis of factors predicting outcome in 1074 patients in OPTN Region 5. Clin Transplant. 2015;29:506-512. [PMID: 25777321 DOI: 10.1111/ctr.12542] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
143 Morris PD, Laurence JM, Yeo D, Crawford M, Strasser SI, Mccaughan GW, Sandroussi C. Can response to locoregional therapy help predict longterm survival after liver transplantation for hepatocellular carcinoma? A systematic review: MORRIS et al. Liver Transpl 2017;23:375-85. [DOI: 10.1002/lt.24689] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]